1
Braydon Charles Guild, Michael Heartlein: mRNA for use in treatment of human genetic diseases. Shire Human Genetic Therapies, Choate Hall & Stewart, Fangli Chen, October 7, 2014: US08853377 (35 worldwide citation)

Compositions for modulating the expression of a protein in a target cell comprising at least one RNA molecule which comprises at least one modification conferring stability to the RNA, as well as related methods, are disclosed.


2

3
Braydon Charles Guild, Michael Heartlein, Frank DeRosa: mRNA for use in treatment of human genetic diseases. Shire Human Genetic Therapies, Choate Hall & Stewart, Fangli Chen, June 23, 2015: US09061021 (3 worldwide citation)

Compositions for modulating the expression of a protein in a target cell comprising at least one RNA molecule which comprises at least one modification conferring stability to the RNA, as well as related methods, are disclosed.


4
Michael Heartlein, Braydon Charles Guild, Frank DeRosa, Carsten Rudolph, Christian Plank, Lianne Smith: CFTR mRNA compositions and related methods and uses. Shire Human Genetic Therapies, Ethris, Choate Hall & Stewart, Fangli Chen, November 10, 2015: US09181321 (2 worldwide citation)

Materials, formulations, production methods, and methods for delivery of CFTR mRNA for induction of CFTR expression, including in the mammalian lung are provided. The present invention is particularly useful for treating cystic fibrosis.


5
Frank DeRosa, Braydon Charles Guild, Michael Heartlein: Lipid-derived neutral nanoparticles. TRANSLATE BIO, Fangli Chen, Proskauer Rose, January 30, 2018: US09877919 (2 worldwide citation)

Disclosed herein are novel lipids and liposomal compositions prepared using such compounds and related methods of neutralizing or otherwise modifying such liposomal compositions. The lipids described herein are useful for example, as liposomal vehicles to facilitate the delivery of encapsulated poly ...


6
Braydon Charles Guild, Michael Heartlein, Frank DeRosa, Jerry Chi Zhang: Cleavable lipids. RaNA Therapeutics, Proskauer Rose, Fangli Chen, August 1, 2017: US09717690 (2 worldwide citation)

Disclosed herein are novel compounds, pharmaceutical compositions comprising such compounds and related methods of their use. The compounds described herein are useful, e.g., as liposomal delivery vehicles to facilitate the delivery of encapsulated polynucleotides to target cells and subsequent tran ...


7
Braydon Charles Guild, Frank DeRosa, Michael Heartlein: MRNA therapy for Fabry disease. Shire Human Genetic Therapies, Choate Hall & Stewart, Fangli Chen, Meaghan E Bychowski, April 12, 2016: US09308281 (1 worldwide citation)

Disclosed herein are compositions and methods for modulating the production of a protein in a target cell. The compositions and methods disclosed herein are capable of ameliorating diseases associated with protein or enzyme deficiencies.


8
Michael Heartlein, Braydon Charles Guild, Frank DeRosa, Carsten Rudolph, Christian Plank, Lianne Smith: CFTR mRNA compositions and related methods and uses. RaNA Therapeutics, Ethris, Fangli Chen, Proskauer Rose, July 25, 2017: US09713626

Pharmaceutical compositions comprising an mRNA-loaded nanoparticle, wherein the mRNA is an in vitro transcribed mRNA and has a coding sequence at least 80% identical to SEQ ID NO: 3, and wherein the mRNA encodes a human cystic fibrosis transmembrane conductance regulator (CFTR) protein comprising th ...


9
Braydon Charles Guild, Frank DeRosa, Michael Heartlein: Pulmonary delivery of mRNA. Shire Human Genetic Therapies, Proskauer Rose, Fangli Chen, March 21, 2017: US09597413

Disclosed herein are compositions and methods for modulating the production of a protein in a target cell. The compositions and methods disclosed herein are capable of ameliorating diseases associated with protein or enzyme deficiencies.


10
Braydon Charles Guild, Michael Heartlein, Frank DeRosa: mRNA for use in treatment of human genetic diseases. TRANSLATE BIO, Fangli Chen, Proskauer Rose, May 1, 2018: US09956271

Compositions for modulating the expression of a protein in a target cell comprising at least one RNA molecule which comprises at least one modification 5 conferring stability to the RNA, as well as related methods, are disclosed.